USP28 inhibitors constitute a class of chemical compounds specifically designed to interact with the enzyme ubiquitin-specific protease 28 (USP28), which plays a critical role in the ubiquitin-proteasome system (UPS). USP28 is one of the many deubiquitinating enzymes (DUBs) that meticulously regulate the process of ubiquitination, a reversible post-translational modification where ubiquitin, a small regulatory protein, is attached to a substrate protein. This attachment serves as a signal for various cellular processes, mostly known for targeting proteins for degradation in the proteasome. However, ubiquitination also plays a part in other cellular processes such as cell cycle regulation, DNA repair, and signal transduction. USP28 inhibitors are designed to bind to the active site of USP28 or to its specific substrate-binding regions, blocking its deubiquitinating activity. By doing so, these inhibitors can modulate the stability of proteins that are substrates of USP28, which can have various downstream effects on cellular functions.
The development of USP28 inhibitors involves a complex interplay of chemistry and biology. The chemical structures of these inhibitors are often complex and require precise molecular design to ensure specificity and efficacy in binding to USP28. The design process typically involves the identification of key residues in the enzyme's active site and the development of molecules that can interact with these residues either through hydrogen bonding, hydrophobic interactions, or other types of chemical bonds. The specificity of USP28 inhibitors is crucial, given that the UPS involves a highly intricate network of enzymes and substrates, and off-target effects could lead to unintended consequences. The potency of these inhibitors is typically measured by their ability to reduce the deubiquitinating activity of USP28 in various in vitro assays, which can include biochemical assays using purified protein or cellular assays where the consequences of USP28 inhibition can be observed in a more complex biological environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Inhibits the Hedgehog (Hh) signaling pathway by binding to Smoothened (SMO), potentially decreasing USP28 stabilization of key signaling proteins like GLI transcription factors, which are regulated by ubiquitination processes that USP28 could affect. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can increase the levels of ubiquitinated proteins, possibly counteracting the deubiquitinating effect of USP28 and promoting the degradation of proteins that USP28 might otherwise stabilize. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $63.00 $128.00 $200.00 | 6 | |
Targets GLI-mediated transcription in the Hedgehog pathway, which might indirectly reduce the USP28-mediated stabilization of GLI proteins by suppressing their transcriptional activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
A specific inhibitor of the proteasome that can lead to the accumulation of ubiquitin-conjugated proteins, potentially affecting the functional role of USP28 in protein turnover. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
A selective proteasome inhibitor that could indirectly affect USP28 function by inhibiting the degradation of ubiquitinated proteins, which USP28 may deubiquitinate. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which is upstream of ERK in the MAPK signaling pathway. This could indirectly affect USP28's role in modulating the stability of proteins involved in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that could alter the AKT signaling pathway, potentially impacting USP28's role in regulating the stability of proteins that are part of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor that could indirectly affect the activity of USP28 by modulating the MAPK/ERK signaling pathway and its associated protein stability. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which can influence the MAPK pathway, indirectly affecting USP28's potential role in the regulation of protein stability within this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could have an indirect effect on USP28 by modulating the stability of p38 MAPK-regulated proteins. | ||||||